Low-Dose Clarithromycin Therapy Modulates Th17 Response In Non-Cystic Fibrosis Bronchiectasis Patients

Lung

Volumn 192, Issue 6, 2014, Pages 849-855

  Fouka, Evangelia ^a,b   Lamprianidou, Eleftheria ^b   Arvanitidis, Konstantinos ^b   Filidou, Eirini ^b   Kolios, George ^b   Miltiades, Paraskevi ^b   Paraskakis, Emmanouil ^b   Antoniadis, Antonios ^c   Kotsianidis, Ioannis ^b   Bouros, Demosthenes ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c General District Hospital of Serres   (Greece)

Author keywords

Bronchiectasis; Exhaled breath condensate; Immunomodulation; Interleukin 17; Macrolides; Th17 cells

Indexed keywords

CLARITHROMYCIN; INTERLEUKIN 17;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BRONCHIECTASIS; BRONCHODILATATION; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; TH17 CELL; BLOOD GAS ANALYSIS; BREATH ANALYSIS; COHORT ANALYSIS; CYSTIC FIBROSIS; CYTOLOGY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; EPIDEMIOLOGY; FOLLOW UP; IMMUNOLOGY; LUNG FUNCTION TEST; LUNG LAVAGE; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GAS ANALYSIS; BREATH TESTS; BRONCHIECTASIS; BRONCHOALVEOLAR LAVAGE FLUID; CLARITHROMYCIN; COHORT STUDIES; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TH17 CELLS; TREATMENT OUTCOME;

EID: 84920982806     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-014-9619-0     Document Type: Article

References (39)

1. Cole PJ (1986) Inflammation: a two-edged sword–the model of bronchiectasis. Eur J Respir Dis Suppl 147:6–15
2. Barker AF (2002) Bronchiectasis. N Engl J Med 346(18):1383–1393
3. Aujla SJ, Dubin PJ, Kolls JK (2007) Interleukin-17 in pulmonary host defense. Exp Lung Res 33(10):507–518
4. Iwakura Y, Nakae S, Saijo S, Ishigame H (2008) The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 226:57–79
5. Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector functions of Th 17 cells. Nature 453(7198):1051–1057
6. Steinman L (2007) A brief history of Th 17, the first major revision in the Th 1/Th 2 hypothesis of T cell-mediated tissue damage. Nat Med 13(2):139–145
7. Vanaudenaerde BM, Verleden SE, Vos R et al (2011) Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders. Am J Respir Crit Care Med 183(8):977–986
8. Dubin PJ, McAllister F, Kolls JK (2007) Is cystic fibrosis a TH17 disease? Inflamm Res 56(6):221–227
9. Kolios G, Manousou P, Bourikas L et al (2006) Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. Eur J Clin Invest 36(10):720–729
10. Rubin BK, Henke MO (2004) Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 125(2 Suppl):70S–78S
11. Shinkai M, Tamaoki J, Kobayashi H et al (2006) Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression. Antimicrob Agents Chemother 50(5):1738–1744
12. Tsang WK, Bilton D (2009) Clinical challenges in managing bronchiectasis. Respirology 14(5):637–650
13. Banerjee D, Honeybourne D, Khair OA (2004) The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med 3(1):59–65
14. Horváth I, Hunt J, Barnes PJ et al (2005) ATS/ERS task force on exhaled breath condensate. exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 26(3):523–548
15. Miller MR, Crapo R, Hankinson J et al (2005) ATS/ERS task force. General considerations for lung function testing. Eur Respir J 26(1):153–161
16. Sun YC, Zhou QT, Yao WZ (2005) Sputum interleukin-17 is increased and associated with airway neutrophilia in patients with severe asthma. Chin Med J (Engl) 118(11):953–956
17. Di Stefano A, Caramori G, Gnemmi I et al (2009) T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 157:316–324
18. McAllister F, Henry A, Kreindler JL et al (2005) Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 175(1):404–412
19. Tan HL, Regamey N, Brown S et al (2011) The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 184(2):252–258
20. Ding FM, Zhu SL, Shen C et al (2012) Low-dose clarithromycin therapy modulates CD4(+) T-cell responses in a mouse model of chronic Pseudomonas aeruginosa lung infection. Respirology 17(4):727–734
21. Tiringer K, Treis A, Fucik P et al (2013) A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 187(6):621–629
22. Wong C, Jayaram L, Karalus N et al (2012) Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 380(9842):660–667
23. Altenburg J, de Graaff CS, Stienstra Y et al (2013) Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 309(12):1251–1259
24. Kushwah R, Gagnon S, Sweezey NB (2013) Intrinsic predisposition of naïve cystic fibrosis T cells to differentiate towards a Th17 phenotype. Respir Res 14:138
25. Ishimatsu Y, Kadota J, Iwashita T et al (2004) Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro. Int J Antimicrob Agents 24(3):247–253
26. Kadota J, Mizunoe S, Kishi K et al (2005) Antibiotic-induced apoptosis in human activated peripheral lymphocytes. Int J Antimicrob Agents 25(3):216–220
27. Loukides S, Kontogianni K, Hillas G et al (2011) Exhaled breath condensate in asthma: from bench to bedside. Curr Med Chem 18(10):1432–1443
28. Borrill ZL, Roy K, Singh D (2008) Exhaled breath condensate biomarkers in COPD. Eur Respir J 32(2):472–486
29. Robroeks CM, Roozeboom MH, de Jong PA et al (2010) Structural lung changes, lung function, and non-invasive inflammatory markers in cystic fibrosis. Pediatr Allergy Immunol 21(3):493–500
30. Karakoc GB, Inal A, Yilmaz M et al (2009) Exhaled breath condensate MMP-9 levels in children with bronchiectasis. Pediatr Pulmonol 44(10):1010–1016
31. Zihlif N, Paraskakis E, Tripoli C et al (2006) Markers of airway inflammation in primary ciliary dyskinesia studied using exhaled breath condensate. Pediatr Pulmonol 41(6):509–514
32. Brodlie M, McKean MC, Johnson GE et al (2011) Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease. Eur Respir J 37(6):1378–1385
33. Eustace A, Smyth LJ, Mitchell L et al (2011) Identification of cells expressing IL-17A and IL-17F in the lungs of patients with COPD. Chest 139(5):1089–1100
34. 2 in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease. Chest 121(1):81–88
35. Tsang KW, Ho PI, Chan KN et al (1999) A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 13(2):361–364
36. Feldman C, Anderson R, Theron AJ et al (1997) Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. Inflammation 21(6):655–665
37. Pukhalsky AL, Shmarina GV, Kapranov NI et al (2004) Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediat Inflamm 13(2):111–117
38. Yalçin E, Kiper N, Ozçelik U et al (2006) Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 31(1):49–55
39. Altenburg J, de Graaff CS, van der Werf TS et al (2011) Immunomodulatory effects of macrolide antibiotics—part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 81(1):75–87